A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Takeda logo

Takeda

Status and phase

Active, not recruiting
Phase 4

Conditions

T-Cell Lymphoma

Treatments

Drug: Brentuximab vedotin

Study type

Interventional

Funder types

Industry

Identifiers

NCT05442554
C25029

Details and patient eligibility

About

The main aim is to check the long-term side effects of treatment with Brentuximab Vedotin and to see if that treatment improves symptoms of cluster of differentiation antigen 30 (CD30-Positive) Cutaneous T-Cell Lymphoma in Chinese adults. Participants will receive brentuximab vedotin through the vein on day 1 of each 21 day cycle up to maximum 16 cycles.

Full description

The drug being tested in this study is called brentuximab vedotin (SGN-35). Brentuximab vedotin is being tested to treat people who have CD30-positive cutaneous T-Cell lymphoma. The study will enroll approximately 10 patients. Participants will receive a single treatment i.e., brentuximab vedotin monotherapy: • Brentuximab vedotin 1.8 mg/kg Participants will be administered with brentuximab vedotin by intravenous (IV) infusion given for approximately 30 minutes on Day 1 of each 21-day cycle up to 16 cycles followed by the end of treatment (EOT) visit 30 days after receiving the final dose of study drug. Participants with progressive disease (PD) at any time during the study will be discontinued from study drug. This multi-center trial will be conducted in China. Participants will remain in this study for approximately 56 weeks.

Enrollment

10 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

1. Histologically- confirmed cluster of differentiation antigen 30 positive (CD30+) disease by local laboratory assessment and pathology review.

2. Participants with primary cutaneous anaplastic large cell lymphoma (pcALCL) who have received prior radiation therapy or at least 1 prior systemic therapy, or participants with mycosis fungoides (MF) who have received at least 1 prior systemic therapy for their disease. 3. Eastern Cooperative Oncology Group (ECOG) performance status of ≤2. 4. Suitable venous access for the study-required blood sampling. 5. Participants must have radiographically or clinically measurable or evaluable disease.

6. Recovered (i.e., Grade 1 toxicity) from the reversible effects of prior antineoplastic therapy.

-Exclusion Criteria:

  • A concurrent diagnosis of systemic anaplastic large cell lymphoma (ALCL), or other non-Hodgkin lymphoma (excluding lymphomatoid papulosis [LyP]).
  • A concurrent diagnosis of sézary syndrome (SS) or high blood tumor burden (B2) disease.
  • Corticosteroid therapy for the treatment of cutaneous T-cell lymphoma (CTCL) within 3 weeks of first dose of study drug.
  • Known hypersensitivity to recombinant proteins, murine proteins, or any excipient contained in the drug formulation.
  • Life-threatening illness unrelated to cancer.
  • Severe central nervous system (CNS), pulmonary, renal, or hepatic disease not related to the participant's cancer.
  • Known active cerebral/meningeal disease, including signs or symptoms of progressive multifocal leukoencephalopathy (PML).
  • Known human immunodeficiency virus (HIV) positive.
  • Known hepatitis B surface antigen positive or known or suspected active hepatitis C infection.
  • Any severe active systemic viral, bacterial, or fungal infection within 1 week before first study drug dose requiring systemic antimicrobial therapy. (Oral antibiotics for prophylaxis are allowed.)
  • Receiving antibody-directed or immunoglobulin-based immune therapy (eg, immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first study drug dose.

Any of the following cardiovascular conditions or values within 6 months before the first dose of study drug:

  • Myocardial infarction within 6 months of enrollment.
  • New York Heart Association (NYHA) Class III or IV heart failure.
  • Evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
  • History of another primary malignancy not in remission for at least 3 years. The following are exempt from the 3-year limit: completely resected in situ carcinoma, such as nonmelanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on Pap smear.
  • Oral retinoid therapy for any indication within 3 weeks of the first dose of study drug.
  • History of pancreatitis or significant risk factors for developing pancreatitis (eg, prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity).

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

10 participants in 1 patient group

Brentuximab Vedotin 1.8 mg/kg
Experimental group
Description:
Brentuximab vedotin 1.8 mg/kg, IV on Day 1 of each 21-day cycle for up to a total of 16 cycles.
Treatment:
Drug: Brentuximab vedotin

Trial contacts and locations

4

Loading...

Central trial contact

Takeda Contact

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems